Project Grant R01CA291965
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$678K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,222 to the University of Pittsburgh to conduct research aimed at understanding how certain gut bacteria can modulate the immune system to enhance the efficacy of immune checkpoint inhibitor (ICI) cancer therapies, specifically in melanoma. The key objectives are to: Determine if ICI-associated bacteria can metabolize dietary tryptophan into aryl hydrocarbon receptor (AhR)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to identify gut microbiome genes and metabolic pathways that impact amino acid homeostasis and the tumor microenvironment, with the goal of developing a synthetic microbial community to prevent and treat cancer. The $606,839 award to Weill Medical College of Cornell University will support a 5-year project to combine bioinformatics, metabolomics, bacterial genetics, and...
This National Cancer Institute (NCI) Project Grant award under the Cancer Research Manpower (CFDA 93.398) program provides $150,701 to the University of Illinois to investigate the relationship between diet, gut microbiome, and cognitive function in breast cancer survivors undergoing chemotherapy. The key objectives are to: Determine how adherence to a Mediterranean diet and the gut microbiome are associated with cognitive function before, during, and after chemotherapy in 30 breast cancer...
The National Cancer Institute (NCI) awarded a $179,988 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Leland Stanford Junior University (Stanford University) for the project "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer." The goal is to identify bacterial functions that can enhance response to immune checkpoint blockade (ICB) cancer immunotherapy. The project will leverage metagenomic data analysis, genetic engineering of...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) in the amount of $400,890 provides funding for research on microbiome-mediated modulation of immune checkpoint molecules in colorectal cancer. The research aims to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate how the gut microbiome impacts immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) in the amount of $112,230 supports research to understand the role of gut microbiome dysbiosis in the development and progression of lung adenocarcinoma (LUAD), the most common type of non-small cell lung cancer. The research aims to determine how gut microbiome dysbiosis impacts inflammation and the immune system during LUAD development, as well as explore the preventive and early...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $281,606 to New York University School of Medicine to conduct research aimed at harnessing gut-derived bacteria to drive anti-tumor immunity in lung cancer. The 5-year project, led by Dr. Rabi Upadhyay, an Assistant Professor at NYU, will investigate the mechanism by which certain gut commensals can trigger systemic anti-tumor immune responses, even in the absence...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research program) provides $537,985 to the University of Texas MD Anderson Cancer Center to deeply characterize the location, distribution, and spatial functionality of microbes within the tumor microenvironment of primary pancreatic ductal adenocarcinoma (PDAC) tumors, as well as their influence on tumor growth, pre-metastatic niche formation, and liver metastasis. The research will utilize...